a month ago
MDGL
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Analyst Ranking
Top 10%
#527 out of 5301 analysts
Average Return
+18.26%
Win Rate
56%49 out of 87
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +520.24% | $8.50 | $52.72 | 2025-10-15 - 2026-03-31 | Strong Buy |
Verastem IncVSTM | +229.72% | $2.49 | $8.21 | 2024-08-13 - 2025-08-12 | Strong Buy |
Mbx Biosciences IncMBX | +208.46% | $13.95 | $43.03 | 2025-10-15 - 2026-06-18 | Strong Buy |
Terns Pharmaceuticals IncTERN | +202.47% | $17.43 | $52.72 | 2025-11-04 - 2026-03-31 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-28 - 2024-06-27 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
a month ago
MBX
a month ago
VTRS
2 months ago
PTGX
3 months ago
SEPN
4 months ago
SRRK
5 months ago
CYTK
6 months ago
PTGX
6 months ago
KYMR
7 months ago
KYMR
7 months ago
MDGL
a year ago
LLY
2 years ago
PFE
2 years ago
EWTX
2 years ago
SRRK
2 years ago
LLY
2 years ago
LLY
2 years ago
LLY
2 years ago
KYMR
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | 3 | Strong Buy | $709.00 | +40.19% | Maintains | a month ago |
Mbx Biosciences IncMBX | 2 | Strong Buy | $70.00 | +62.68% | Maintains | a month ago |
Viatris IncVTRS | 2 | Strong Buy | $20.00 | +30.12% | Maintains | a month ago |
Absci CorpABSI | 1 | Strong Buy | $11.00 | +48.45% | Maintains | a month ago |
Protagonist Therapeutics IncPTGX | 5 | Strong Buy | $121.00 | +7.21% | Maintains | 2 months ago |
Biogen IncBIIB | 7 | Hold | $189.00 | -3.86% | Maintains | 2 months ago |
Terns Pharmaceuticals IncTERN | 5 | Hold | $53.00 | +0.09% | Downgrades | 3 months ago |
Inventiva SaIVA | 1 | Strong Buy | $13.00 | +264.15% | Initiates Coverage On | 3 months ago |
Septerna IncSEPN | 2 | Strong Buy | $35.00 | -3.23% | Maintains | 3 months ago |
Scholar Rock Holding CorpSRRK | 6 | Strong Buy | $55.00 | +16.21% | Maintains | 4 months ago |
Cytokinetics IncCYTK | 5 | Strong Buy | $92.00 | +16.78% | Maintains | 5 months ago |
Kymera Therapeutics IncKYMR | 6 | Strong Buy | $116.00 | +28.28% | Maintains | 6 months ago |
Incyte CorpINCY | 12 | Hold | $93.00 | -5.31% | Reiterates | 8 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Strong Buy | $812.00 | +33.13% | Maintains | 10 months ago |
Arvinas IncARVN | 1 | Hold | $11.00 | N/A | Downgrades | a year ago |
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | N/A | Maintains | a year ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $1,038.00 | N/A | Maintains | a year ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | N/A | Maintains | a year ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | N/A | Maintains | 2 years ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | N/A | Maintains | 2 years ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | N/A | Upgrades | 2 years ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Affimed NvAFMDQ | 2 | Strong Buy | $60.00 | N/A | Maintains | 3 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 3 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.